Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure

By afschroeder • September 20, 2025

Green L, Armstrong A, Han G, Jacobson A. Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure. Dermatol Ther (Heidelb). 2025 Sep 19. doi: 10.1007/s13555-025-01533-9. Epub ahead of print. PMID: 40971026.

Tags: Biologic failure, Dermatology, ixekizumab, Publications, Quality of Life, Refractory, secukinumab, Therapy switching, tnf inhibitor

Improvement of pruritus associated with erythrocytosis in transmasculine patients undergoing gender-affirming therapy with phlebotomy: a report of two patients

Galamgam J, Baroni E, Tsai S, Cheng CE. Improvement of pruritus associated with erythrocytosis in transmasculine patients undergoing gender-affirming therapy with phlebotomy: a report of[...]

Landscape of dermatology education in allopathic medical schools across the United States

Poppens M, McClain W, Collier E, Cheng K, Hogeling M. Landscape of dermatology education in allopathic medical schools across the United States. Dermatol Online J.[...]

Doxycycline-Induced Phototoxicity

Boyd G, Cheng C. Doxycycline-Induced Phototoxicity. N Engl J Med. 2025 Sep 25;393(12):e19. doi: 10.1056/NEJMicm2506434. PMID: 40991903.